SABS: SAB Biotherapeutics Inc. Analyst Consensus Forecast
SAB Biotherapeutics (SABS) is developing an innovative method for producing human antibodies via genetically modified animals, leveraging successful diabetes drug trials and grants. The business's high growth potential stems from the ability to rapidly develop treatments for various infections at low costs. The current metric stands at 11.73, and pricing power will emerge following regulatory approval. This chart illustrates the company's market dynamics reflected in its price action.
Analytical breakdowns for SAB Biotherapeutics, Inc (SABS)
- price and consensus price forecast:
- market capitalization information:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity SAB Biotherapeutics|SABS - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital SAB Biotherapeutics Inc|SABS - Company Aggregate Debts|Debts to Book Capitalization SAB Biotherapeutics, Inc|SABS - Company Long-Term Debt|Company Short-Term Loans and Borrowings SAB Biotherapeutics|Quick Liquidity Indicator sabbiotherapeutics.com
- financial results and valuation multiples details:
SABS - Net Profit|Projected Future Earnings SAB Biotherapeutics|SABS - Price to Earnings Ratio|Future Price to Earnings Multiple SAB Biotherapeutics Inc.|SABS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio SAB Biotherapeutics, Inc|SABS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months SAB Biotherapeutics|SABS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months sabbiotherapeutics.com|SABS - Net earnings per share growth this year|Earnings growth forecast for next year SAB Biotherapeutics
General company analysis:SABS sabbiotherapeutics.com
To minimize risks in long-term investing, it is critical to weigh market volatility against the resilience of average target price estimates from institutional experts. The current consensus forecast reflects the aggregate fundamental value of SAB Biotherapeutics (SABS), where stable targets amid falling quotes confirm the value of the Inertia platform and its patents, which guarantee monopoly income from antibody production and high intrinsic business strength.
Competitors of SAB Biotherapeutics
Analyst Median Target argenx.com|Analyst Consensus Forecast BNTX (BioNTech)|Analyst Consensus Forecast Abivax SA ABVX|ADMA Bio - Analyst Consensus Forecast|PTGX: Price Target Chart|Immunovant, Inc. (IMVT) - Price Target Chart|KNSA - Analyst Median Target|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|JBIO - Price Target Chart|Analyst Median Target Aclaris Therapeutics, Inc ACRS|KYTX: Analyst Consensus Forecast|tizianalifesciences.com (TLSA) - Analyst Consensus Forecast|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Price Target Chart VTYX|Consensus Target THTX (Theratechnologies Inc)|AVTX (Avalo Therapeutics Inc) - Fair Value Consensus|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|agenusbio.com - Price Target Chart|Climb Bio - Analyst Consensus Forecast|Analyst Median Target zurabio.com ZURA|aTyr (ATYR) - Price Target Chart|Average Forecast Price Adagene Inc. (ADAG)|Consensus Target IMA|STTK (Shattuck Therapeutics) - Analyst Forecast Prices|Analyst Consensus Forecast EQ|CNTB (connectbiopharm.com) - Fair Value Consensus|Analyst Consensus Forecast IMUX (Immunic)|Atara Biotherapeutics, Inc. (ATRA) - Average Forecast Price|IFRX - Price Target Chart|Fair Value Consensus XFOR (x4pharma.com)|ACET: Analyst Consensus Forecast|Celularity (CELU) - Analyst Consensus Forecast|Price Target Chart INmune Bio Corp|Barinthus Biotherapeutics Corp - Forecast Levels Chart|Analyst Consensus Forecast KZR|AKTX - Average Forecast Price|Enlivex Therapeutics Ltd. - Consensus Target|Analyst Consensus Forecast Q32 Bio Inc QTTB|GOVX: Consensus Target|Edesa Biotech Corp - Analyst Forecast Prices|IBIO: Analyst Consensus Forecast|CARM - Analyst Median Target|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Consensus Target Bolt Bio (BOLT)|Price Target Chart HCW Biologics Inc. (HCWB)|Analyst Median Target aptevotherapeutics.com|Price Target Chart AIM ImmunoTech AIM|Analyst Median Target Aditxt Inc. (ADTX)|GRI Bio - Analyst Consensus Forecast|XRTX - Analyst Consensus Forecast|HIND: Analyst Consensus Forecast|REVB (Revelation Biosciences Corp) - Price Target Chart|Price Target Chart Indaptus Therapeutics|scinai.com (SCNI) - Analyst Median Target|Price Target Chart CalciMedica, Inc. (CALI)|AFMD: Forecast Levels Chart|Analyst Consensus Forecast ALLK (Allakos)|Fair Value Consensus HOOK|IGM Bio - Analyst Consensus Forecast|ITOS - Analyst Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|TC BioPharm (Holdings) Plc - Fair Value Consensus|Price Target Chart Third Harmonic Bio, Inc
